Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Malignant Melanoma

  Free Subscription


Articles published in Melanoma Res

Retrieve available abstracts of 302 articles:
HTML format



Single Articles


    October 2024

  1. Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma: Erratum.
    Melanoma Res. 2024;34:473.
    PubMed    


  2. MATTIUZZI C, Lippi G
    The death rate for melanoma remained unchanged in the USA during the coronavirus disease 2019 pandemic.
    Melanoma Res. 2024;34:472.
    PubMed    


    August 2024
  3. STOFF R, Markovic SN, McWilliams RR, Kottschade LA, et al
    Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting.
    Melanoma Res. 2024 Aug 30. doi: 10.1097/CMR.0000000000000997.
    PubMed     Abstract available


  4. KIM I, Oh J, Yoon S, Han MY, et al
    Pediatric melanoma incidence and survival: a fifteen-year nationwide retrospective cohort study in Korea (2004-2019).
    Melanoma Res. 2024 Aug 30. doi: 10.1097/CMR.0000000000001000.
    PubMed     Abstract available


  5. ZWEEDIJK BE, Schurink AW, van Dalen T, van Ginhoven TM, et al
    Transcutaneous sentinel lymph node detection in skin melanoma with near-infrared fluorescence imaging using indocyanine green.
    Melanoma Res. 2024 Aug 2. doi: 10.1097/CMR.0000000000000994.
    PubMed     Abstract available


  6. WANG S, Zhou H, Ma Y, Jin S, et al
    A retrospective study of clinicopathological and prognostic characteristics in 177 Chinese patients with acral melanoma: heterogeneity based on tumor site.
    Melanoma Res. 2024;34:390-392.
    PubMed    


  7. KIBBIE JJ, Zita SM, Dellavalle RP, Dunnick CA, et al
    The number needed to biopsy for cutaneous melanoma in academic dermatology clinics.
    Melanoma Res. 2024;34:350-354.
    PubMed     Abstract available


  8. ORLANDI E, Ceccuzzi L, Belpinati F, Rodolfo M, et al
    Sex-dependent interaction of PTGS2 with miR-146a as risk factor for melanoma and the impact of sex hormones in gene expression in skin cells.
    Melanoma Res. 2024;34:296-306.
    PubMed     Abstract available


  9. OZLUK AA, Gunenc D, Yildirim SS, Karaca B, et al
    Tocilizumab in the treatment of steroid refractory immune-related hepatotoxicity: a case series and review of the literature.
    Melanoma Res. 2024;34:335-342.
    PubMed     Abstract available


    July 2024
  10. ZHANG S, Liu Z, Zhu D
    Development and validation of prognostic nomogram in pediatric melanoma: a population-based study.
    Melanoma Res. 2024 Jul 31. doi: 10.1097/CMR.0000000000000993.
    PubMed     Abstract available


  11. ELMES JB, Davis JM, Musselwhite LW, Chiad Z, et al
    Hemophagocytic lymphohistiocytosis induced by dabrafenib-trametinib in a patient with metastatic melanoma: a case report and pharmacovigilance analysis.
    Melanoma Res. 2024 Jul 22. doi: 10.1097/CMR.0000000000000992.
    PubMed     Abstract available


  12. TSIMPIDAKIS A, Koumprentziotis IA, Mastoraki E, Plaka M, et al
    Exacerbation of Kaposi sarcoma following BRAF/MEK inhibitor therapy in a melanoma patient: a case report and mechanistic insight.
    Melanoma Res. 2024 Jul 22. doi: 10.1097/CMR.0000000000000991.
    PubMed     Abstract available


  13. CHANDRASEKARAN S, Ling YL, Tang J
    Real-world use and outcomes of targeted therapy and immunotherapy for adjuvant treatment of BRAF-mutated melanoma patients in the United States.
    Melanoma Res. 2024 Jul 16. doi: 10.1097/CMR.0000000000000990.
    PubMed     Abstract available


  14. FOKKEN C, Silbern I, Shomroni O, Pan KT, et al
    Interfering with aggregated alpha-synuclein in advanced melanoma leads to a major upregulation of MHC class II proteins.
    Melanoma Res. 2024 Jul 2. doi: 10.1097/CMR.0000000000000982.
    PubMed     Abstract available


    June 2024
  15. LOCHRIN SE, Cugliari MK, Yeh R, Shoushtari AN, et al
    Efficacy of axitinib in a US cohort of patients with programmed cell death protein 1-resistant mucosal melanoma.
    Melanoma Res. 2024 Jun 28. doi: 10.1097/CMR.0000000000000988.
    PubMed     Abstract available


  16. DE GIORGI V, Cecchi G, Perillo G, Zuccaro B, et al
    Synchronous double primary vulvar melanoma: a not so rare possibility. A clinical and dermoscopic case study.
    Melanoma Res. 2024 Jun 24. doi: 10.1097/CMR.0000000000000989.
    PubMed     Abstract available


  17. ASHER N, Bar-Hai N, Ben-Betzalel G, Stoff R, et al
    Exploring the clinical significance of specific immune-related adverse events in melanoma patients undergoing immune checkpoint inhibitor therapy.
    Melanoma Res. 2024 Jun 24. doi: 10.1097/CMR.0000000000000985.
    PubMed     Abstract available


  18. SHEMER M, Shimonovitz M, Furer R, Abu-Abeid A, et al
    Long-term outcomes and patterns of recurrence in patients with thin melanoma and a negative sentinel lymph node biopsy: a single-center experience.
    Melanoma Res. 2024 Jun 14. doi: 10.1097/CMR.0000000000000986.
    PubMed     Abstract available


  19. BUSTAMANTE P, Coblentz J, Mastromonaco C, Youhnovska E, et al
    Comprehensive clinical imaging, histopathological analysis and liquid biopsy-based surveillance of human uveal melanoma in a prolonged rabbit xenograft model.
    Melanoma Res. 2024 Jun 7. doi: 10.1097/CMR.0000000000000964.
    PubMed     Abstract available


  20. LIU H, Jiang H, Shan Q
    Reflectance confocal microscopy versus dermoscopy for the diagnosis of cutaneous melanoma: a head-to-head comparative meta-analysis.
    Melanoma Res. 2024 Jun 7. doi: 10.1097/CMR.0000000000000980.
    PubMed     Abstract available


  21. LUO P, Guo R, Gao D, Zhang Q, et al
    Causal relationship between sex hormones and cutaneous melanoma: a two-sample Mendelian randomized study.
    Melanoma Res. 2024 Jun 5. doi: 10.1097/CMR.0000000000000983.
    PubMed     Abstract available


  22. DINI F, Susini P, Zuccaro B, Nisi G, et al
    Head and neck melanoma: the eyelid region has a better prognosis and easier management: a retrospective survey and systematic review.
    Melanoma Res. 2024 Jun 3. doi: 10.1097/CMR.0000000000000984.
    PubMed     Abstract available


  23. SHAH H, Parisi R, Everdell E, Feustel P, et al
    The effect of COVID-19 on early melanoma detection.
    Melanoma Res. 2024;34:283-284.
    PubMed    


    May 2024
  24. SAMLOWSKI W, Silver MA, Hohlbauch A, Zhang S, et al
    Relationships between survival and real-world recurrence-free survival or distant metastasis-free survival among patients with completely resected stage IIB or IIC melanoma.
    Melanoma Res. 2024 May 27. doi: 10.1097/CMR.0000000000000962.
    PubMed     Abstract available


  25. VANDER MIJNSBRUGGE AS, Cerckel J, Dirven I, Tijtgat J, et al
    Regorafenib in patients with pretreated advanced melanoma: a single-center case series.
    Melanoma Res. 2024 May 27. doi: 10.1097/CMR.0000000000000977.
    PubMed     Abstract available


  26. INDINI A, Gueli R, Cerati M, Rijavec E, et al
    Cytomegalovirus gastritis as a rare adverse event during combined ipilimumab and nivolumab in a patient with melanoma.
    Melanoma Res. 2024 May 20. doi: 10.1097/CMR.0000000000000981.
    PubMed     Abstract available


  27. ALBERTINI MR, Zuleger CL, Ranheim EA, Shiyanbola O, et al
    Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma.
    Melanoma Res. 2024 May 20. doi: 10.1097/CMR.0000000000000975.
    PubMed     Abstract available


    April 2024
  28. GAO Y, Wang Y, Luo Y, Zhang Y, et al
    Pretreatment CD8+PD-1+ to CD4+PD-1+ ratio is associated with the prognosis of advanced melanoma patients treated with PD-1 inhibitors.
    Melanoma Res. 2024 Apr 22. doi: 10.1097/CMR.0000000000000972.
    PubMed     Abstract available


  29. WU LW, Tao JJ, McDonnell D, Izar B, et al
    Pseudoprogression in a patient with metastatic melanoma treated with PD-1 and LAG-3 inhibition.
    Melanoma Res. 2024 Apr 18. doi: 10.1097/CMR.0000000000000974.
    PubMed     Abstract available


  30. SUWAJANAKORN D, Lane AM, Go AK, Hartley CD, et al
    Impact of gene expression profiling on diagnosis and survival after metastasis in patients with uveal melanoma.
    Melanoma Res. 2024 Apr 5. doi: 10.1097/CMR.0000000000000971.
    PubMed     Abstract available


  31. HENNEMANN A, Puzenat E, Decreuse M, Vuillier F, et al
    Intracranial hemorrhage caused by dabrafenib and trametinib therapy for metastatic melanoma.
    Melanoma Res. 2024 Apr 5. doi: 10.1097/CMR.0000000000000820.
    PubMed     Abstract available


  32. MAIONE V, Perantoni M, Bettolini L, Bighetti S, et al
    Influence of regression, its extent and tumor-infiltrating lymphocytes on sentinel node status, relapse, and survival in a 10-year retrospective study of melanoma patients.
    Melanoma Res. 2024 Apr 2. doi: 10.1097/CMR.0000000000000970.
    PubMed     Abstract available


    March 2024
  33. KODALI N, Bhattaru A, Blanchard I, Sharma Y, et al
    Assessing melanoma prognosis: the interplay between patient profiles, survival, and BRAF, NRAS, KIT, and TWT mutations in a retrospective multi-study analysis.
    Melanoma Res. 2024 Mar 29. doi: 10.1097/CMR.0000000000000968.
    PubMed     Abstract available


  34. FABRE M, Lamoureux A, Meunier L, Samaran Q, et al
    Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey.
    Melanoma Res. 2024 Mar 28. doi: 10.1097/CMR.0000000000000963.
    PubMed     Abstract available


  35. NEKKANTI SS, Nusrath S, Jarang R, Rayani BK, et al
    Feasibility and efficacy of indocyanine green in monitoring systemic drug leakage during isolated limb perfusion for recurrent melanoma of extremity.
    Melanoma Res. 2024 Mar 15. doi: 10.1097/CMR.0000000000000967.
    PubMed     Abstract available


  36. LEROY M, Desmedt E, Deramoudt L, Vasseur M, et al
    Retrospective comparison of a weight-based dose every 2 weeks with a fixed dose every month: a real-life analysis of nivolumab in the treatment of advanced melanoma.
    Melanoma Res. 2024 Mar 15. doi: 10.1097/CMR.0000000000000965.
    PubMed     Abstract available


  37. WANG P, Liu T, Zhang Q, Luo P, et al
    Genetic causal relationship between gut microbiota and cutaneous melanoma: a two-sample Mendelian randomization study.
    Melanoma Res. 2024 Mar 11. doi: 10.1097/CMR.0000000000000960.
    PubMed     Abstract available


  38. NG CA, Luckett T, Mulhern B, Kee D, et al
    What matters most to people with metastatic uveal melanoma? A qualitative study to inform future measurement of health-related quality of life.
    Melanoma Res. 2024 Mar 5. doi: 10.1097/CMR.0000000000000961.
    PubMed     Abstract available


    February 2024
  39. DE PINTO G, Mignozzi S, La Vecchia C, Levi F, et al
    Global trends in cutaneous malignant melanoma incidence and mortality.
    Melanoma Res. 2024 Feb 21. doi: 10.1097/CMR.0000000000000959.
    PubMed     Abstract available


  40. TEIXEIRA RJ, de Souza VG, Sorroche BP, Paes VG, et al
    Immunohistochemistry assessment of tissue neutrophil-to-lymphocyte ratio (tNLR) predicts outcomes in melanoma patients treated with anti-programmed cell death 1 therapy.
    Melanoma Res. 2024 Feb 16. doi: 10.1097/CMR.0000000000000958.
    PubMed     Abstract available


  41. ZHANG W, Wang S
    Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in skin cutaneous melanoma.
    Melanoma Res. 2024 Feb 16. doi: 10.1097/CMR.0000000000000957.
    PubMed     Abstract available


  42. DE SMEDT J, Aura C, Van Kelst S, Janssen L, et al
    Clinical and genetic determinants of vitamin D receptor expression in cutaneous melanoma patients.
    Melanoma Res. 2024 Feb 13. doi: 10.1097/CMR.0000000000000929.
    PubMed     Abstract available


  43. DELZENNE G, Boileau M, Jamme P, Farchi O, et al
    Relevance of detection of RAF fusion transcripts in pan-negative melanoma in routine practice.
    Melanoma Res. 2024 Feb 7. doi: 10.1097/CMR.0000000000000955.
    PubMed     Abstract available


  44. ERCAN A, Yalcin CE
    Neonatal cutaneous melanoma with cutaneous metastasis: a case report and review of literature.
    Melanoma Res. 2024 Feb 7. doi: 10.1097/CMR.0000000000000956.
    PubMed     Abstract available


  45. DIAZ MJ, Quach J, Song J, Milanovic S, et al
    Hypoxic transcriptomes predict survival and tumor-infiltrating immune cell composition in cutaneous melanoma.
    Melanoma Res. 2024 Feb 7. doi: 10.1097/CMR.0000000000000938.
    PubMed     Abstract available


  46. GEIGER CE, Mrabet-Dahbi S, Berger I
    The BRAF and NRAS status among distinct metastases of malignant melanoma differ significantly independent of tissue origin and temporal occurrence. Possible effect on clinical relevance?
    Melanoma Res. 2024;34:85-87.
    PubMed    


  47. ROSTER K, Thang C, Islam S, Lipner SR, et al
    Underreporting of acral lentiginous melanoma in studies informing American Joint Committee on Cancer Staging System Guidelines: a review of 150 cited studies.
    Melanoma Res. 2024;34:84-88.
    PubMed    


  48. DUARTE R, Trigo F, Luz I, Santos P, et al
    Small-vessel vasculitis leading to severe acute kidney injury after ipilimumab: a case report.
    Melanoma Res. 2024;34:76-79.
    PubMed     Abstract available


    January 2024
  49. DAVIDSON TM, Hieken TJ, Glasgow AE, Habermann EB, et al
    Pregnancy-associated melanoma: characteristics and outcomes from 2002 to 2020.
    Melanoma Res. 2024 Jan 23. doi: 10.1097/CMR.0000000000000953.
    PubMed     Abstract available


  50. KOSTAKI M, Plaka M, Befon A, Dessinioti C, et al
    Simultaneous melanomas in the setting of multiple primary melanomas.
    Melanoma Res. 2024 Jan 15. doi: 10.1097/CMR.0000000000000954.
    PubMed     Abstract available


  51. PARISA S, Amirhossein I, Hamed YS, Javad F, et al
    The effect of microRNA-9 overexpression on inhibition of melanoma cancer stem cells tumorigenicity.
    Melanoma Res. 2024 Jan 15. doi: 10.1097/CMR.0000000000000931.
    PubMed     Abstract available


  52. KO B, Tao K, Brennan L, Rakhade S, et al
    Evaluating the efficacy of combination and single-agent immunotherapies in real-world patterns of disease progression and survival of metastatic melanoma patients.
    Melanoma Res. 2024 Jan 5. doi: 10.1097/CMR.0000000000000945.
    PubMed     Abstract available


    December 2023
  53. LOUVEAU B, Reger De Moura C, Jouenne F, Sadoux A, et al
    Combined PDE4+MEK inhibition shows antiproliferative effects in NRASQ61 mutated melanoma preclinical models.
    Melanoma Res. 2023 Dec 22. doi: 10.1097/CMR.0000000000000950.
    PubMed     Abstract available


  54. YEE J, Rosendahl C, Aoude LG
    The role of artificial intelligence and convolutional neural networks in the management of melanoma: a clinical, pathological, and radiological perspective.
    Melanoma Res. 2023 Dec 22. doi: 10.1097/CMR.0000000000000951.
    PubMed     Abstract available


  55. ROSHARDT PRIETO NM, Turko P, Zellweger C, Nguyen-Kim TDL, et al
    Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma.
    Melanoma Res. 2023 Dec 19. doi: 10.1097/CMR.0000000000000952.
    PubMed     Abstract available


  56. YAN J, Wang H, Lu X, Li F, et al
    Development and validation of a nomogram for elderly patients with ulcerative melanoma.
    Melanoma Res. 2023 Dec 13. doi: 10.1097/CMR.0000000000000940.
    PubMed     Abstract available


  57. BAFALOUKOS D, Kouzis P, Gouveris P, Boukovinas I, et al
    Real-world management practices and characteristics of patients with advanced melanoma initiated on immuno-oncology or targeted therapy in the first-line setting during the period 2015-2018 in Greece. The 'SUMMER' study: a retrospective multicenter ch
    Melanoma Res. 2023 Dec 13. doi: 10.1097/CMR.0000000000000949.
    PubMed     Abstract available


  58. RICHTIG E, Nguyen VA, Koelblinger P, Wolf I, et al
    Dabrafenib plus trametinib in unselected advanced BRAF V600-mut melanoma: a non-interventional, multicenter, prospective trial.
    Melanoma Res. 2023 Dec 13. doi: 10.1097/CMR.0000000000000948.
    PubMed     Abstract available


  59. SWITZER B, Puzanov I, Gandhi S, Repasky EA, et al
    Targeting beta-adrenergic receptor pathways in melanoma: how stress modulates oncogenic immunity.
    Melanoma Res. 2023 Dec 4. doi: 10.1097/CMR.0000000000000943.
    PubMed     Abstract available


  60. PARISI R, Shah H, Everdell E, Feustel P, et al
    First-time office visit for suspicious skin lesion evaluation as a predictor of high-risk melanoma.
    Melanoma Res. 2023;33:555-556.
    PubMed    


  61. CARMONA-ROCHA E, Sullivan I, Yelamos O
    Vitiligo-like hypopigmentation induced by dabrafenib-trametinib: a potential marker for clinical response.
    Melanoma Res. 2023;33:553-555.
    PubMed    


  62. TAN SX, Chong S, Rowe C, Claeson M, et al
    pSTAT5 is associated with improved survival in patients with thick or ulcerated primary cutaneous melanoma.
    Melanoma Res. 2023;33:506-513.
    PubMed     Abstract available


  63. MEYER SN, Simmons E, Studer AC, Rauen KA, et al
    Melanocytic neoplasms in neurofibromatosis type 1: a systematic review.
    Melanoma Res. 2023;33:437-446.
    PubMed     Abstract available


  64. VIGNESWARAN G, Malalasekera W, Smith V, Gibson T, et al
    Quality of life after melphalan percutaneous hepatic perfusion for patients with metastatic Uveal Melanoma.
    Melanoma Res. 2023 Dec 1. doi: 10.1097/CMR.0000000000000947.
    PubMed     Abstract available


    November 2023
  65. STAHLIE EHA, Zijlker LP, Wouters MWJM, Schrage YM, et al
    Real-world relapse-free survival data on adjuvant anti-PD-1 therapy for patients with newly diagnosed and recurrent stage III melanoma.
    Melanoma Res. 2023 Nov 28. doi: 10.1097/CMR.0000000000000946.
    PubMed     Abstract available


  66. MEZOLAKI NE, Baltas E, Ocsai HL, Varga A, et al
    Tumour regression predicts better response to interferon therapy in melanoma patients: a retrospective single centre study.
    Melanoma Res. 2023 Nov 13. doi: 10.1097/CMR.0000000000000935.
    PubMed     Abstract available


  67. KAHLER KC, Debus D, Schley G, Goppner D, et al
    Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNIS.
    Melanoma Res. 2023 Nov 13. doi: 10.1097/CMR.0000000000000908.
    PubMed     Abstract available


  68. PAOLINO G, Carugno A, Rongioletti F, Ponzoni M, et al
    Bone marrow metastases: a systematic review of a neglected involvement in malignant melanoma.
    Melanoma Res. 2023 Nov 8. doi: 10.1097/CMR.0000000000000942.
    PubMed     Abstract available


  69. CHEN W, Yang C, Chen B, Xi M, et al
    Management of metastatic bone disease of melanoma.
    Melanoma Res. 2023 Nov 8. doi: 10.1097/CMR.0000000000000937.
    PubMed     Abstract available


  70. TAIBO A, Paradela S, Suanzes-Hernandez J, Balboa-Barreiro V, et al
    Prognosis of CDKN2A germline mutation in patients with familial melanoma: a systematic review and meta-analysis.
    Melanoma Res. 2023 Nov 2. doi: 10.1097/CMR.0000000000000920.
    PubMed     Abstract available


  71. GAMBICHLER T, Iordanou M, Becker JC, Susok L, et al
    Intratumoural and systemic inflammation as predictors for treatment response in BRAF-mutated melanoma patients under targeted therapies.
    Melanoma Res. 2023 Nov 2. doi: 10.1097/CMR.0000000000000934.
    PubMed     Abstract available


  72. KIM HE, Kim J, Park HK, Lee JB, et al
    Correlations between inflammatory cytokine levels and degree of pigmentation in acral melanomas.
    Melanoma Res. 2023 Nov 2. doi: 10.1097/CMR.0000000000000939.
    PubMed     Abstract available


  73. BENESCH MGK, Skitzki JJ
    Impact of anesthesia choice in cutaneous melanoma surgery.
    Melanoma Res. 2023 Nov 2. doi: 10.1097/CMR.0000000000000936.
    PubMed     Abstract available


  74. KOHL LM, Sumpter TL
    Melanomas and mast cells: an ambiguous relationship.
    Melanoma Res. 2023 Nov 2. doi: 10.1097/CMR.0000000000000932.
    PubMed     Abstract available


    October 2023
  75. CAO Y, Afzal MZ, Gutmann EJ, Shirai K, et al
    Rare immune-related adverse events in a patient with metastatic melanoma: a case report highlighting sarcoidosis-like reactions triggered by immune-checkpoint inhibitors.
    Melanoma Res. 2023 Oct 13. doi: 10.1097/CMR.0000000000000925.
    PubMed     Abstract available


  76. SADA I, Harada Y, Hiyama T, Mizukami M, et al
    Uveitis associated with immune checkpoint inhibitors or BRAF/MEK inhibitors in patients with malignant melanoma.
    Melanoma Res. 2023 Oct 2. doi: 10.1097/CMR.0000000000000933.
    PubMed     Abstract available


  77. RUBATTO M, Borriello S, Sciamarrelli N, Pala V, et al
    Exploring the role of epigenetic alterations and non-coding RNAs in melanoma pathogenesis and therapeutic strategies.
    Melanoma Res. 2023 Oct 2. doi: 10.1097/CMR.0000000000000926.
    PubMed     Abstract available


  78. PHAM JP, Dwyer L, Phan K, Menzies AM, et al
    Efficacy of topical diphencyprone for melanoma in-transit metastases: a systematic review and meta-analysis.
    Melanoma Res. 2023;33:434-436.
    PubMed    


  79. OZLUK AA, Karateke M, Sanli UA, Karaca B, et al
    Efficacy of local ablative therapies in patients with solid tumors treated with immune checkpoint inhibitors and oligoprogression: a single-center analysis.
    Melanoma Res. 2023;33:417-421.
    PubMed     Abstract available


    September 2023
  80. BOUDREAU MW, Tonogai EJ, Schane CP, Xi MX, et al
    The combination of PAC-1 and entrectinib for the treatment of metastatic uveal melanoma.
    Melanoma Res. 2023 Sep 22. doi: 10.1097/CMR.0000000000000927.
    PubMed     Abstract available


  81. SEGURA S, Podlipnik S, Boada A, Marti RM, et al
    Melanoma-specific survival in worse in the elderly: a multicentric cohort study.
    Melanoma Res. 2023 Sep 4. doi: 10.1097/CMR.0000000000000923.
    PubMed     Abstract available


  82. LIN Z, Shen H, Liu X, Ma W, et al
    Recent advances of artificial intelligence in melanoma clinical practice.
    Melanoma Res. 2023 Sep 4. doi: 10.1097/CMR.0000000000000922.
    PubMed     Abstract available


  83. UEMATSU M, Nakajima H, Hosono A, Kiyohara H, et al
    Safety of immune checkpoint inhibitors after proton beam therapy in head and neck mucosal melanoma: a case series.
    Melanoma Res. 2023 Sep 4. doi: 10.1097/CMR.0000000000000924.
    PubMed     Abstract available


    August 2023
  84. LUO S, Xie C, Lin N, Lin D, et al
    Cost-effectiveness analysis of an orphan drug-tebentafusp in patients with metastatic uveal melanoma and a call for value-based pricing.
    Melanoma Res. 2023 Aug 25. doi: 10.1097/CMR.0000000000000919.
    PubMed     Abstract available


  85. MATTEI J, Trindade EN, Chedid MF
    Mucosal melanoma: from molecular landscape to current treatment strategies.
    Melanoma Res. 2023 Aug 25. doi: 10.1097/CMR.0000000000000916.
    PubMed     Abstract available


  86. MILEY DR, Andrews-Pfannkoch CM, Pulido JS, Erickson SA, et al
    Direct early growth response-1 knockdown decreases melanoma viability independent of mitogen-activated extracellular signal-related kinase inhibition.
    Melanoma Res. 2023 Aug 25. doi: 10.1097/CMR.0000000000000921.
    PubMed     Abstract available


  87. LIU M, Lan Y, Zhang H, Zhang X, et al
    Telomere length is associated with increased risk of cutaneous melanoma: a Mendelian randomization study.
    Melanoma Res. 2023 Aug 25. doi: 10.1097/CMR.0000000000000917.
    PubMed     Abstract available


  88. GJORUP CA, Pires da Silva I, Martin L, Stretch JR, et al
    Definitive treatment with PD-1 blockade and radiation therapy of unresected primary desmoplastic melanoma of the nose.
    Melanoma Res. 2023 Aug 3. doi: 10.1097/CMR.0000000000000905.
    PubMed     Abstract available


  89. AUGUSTYN K, Joseph J, Patel AB, Razmandi A, et al
    Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice.
    Melanoma Res. 2023 Aug 3. doi: 10.1097/CMR.0000000000000891.
    PubMed     Abstract available


    July 2023
  90. GLINKINA KA, Teunisse AFAS, Gelmi MC, de Vries J, et al
    Combined Mcl-1 and YAP1/TAZ inhibition for treatment of metastatic uveal melanoma.
    Melanoma Res. 2023 Jul 18. doi: 10.1097/CMR.0000000000000911.
    PubMed     Abstract available


  91. FELICI C, Passarelli A, Cafforio P, Racanelli V, et al
    Lenalidomide arrests cell cycle and modulates PD1-dependent downstream mTOR intracellular signals in melanoma cells.
    Melanoma Res. 2023 Jul 12. doi: 10.1097/CMR.0000000000000913.
    PubMed     Abstract available


  92. PELIZZARI G, Bertoli E, Buriolla S, Vitale MG, et al
    Estimating survival in patients with melanoma brain metastases: prognostic value of lactate dehydrogenase.
    Melanoma Res. 2023 Jul 3. doi: 10.1097/CMR.0000000000000907.
    PubMed     Abstract available


    June 2023
  93. GIRONI LC, Esposto E, Zottarelli F, Giorgione R, et al
    Temporal correlation between the first melanoma and the first noncutaneous tumor in CKDN2A genotyped patients.
    Melanoma Res. 2023 Jun 21. doi: 10.1097/CMR.0000000000000906.
    PubMed     Abstract available


  94. HE K, Hong DS, Ke D, Kebriaei P, et al
    Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report.
    Melanoma Res. 2023 Jun 16. doi: 10.1097/CMR.0000000000000869.
    PubMed     Abstract available


  95. ASSEFA W, Muluye S, Assefa A, Alemu Y, et al
    A glimpse at locally advanced melanomas in the settings of poverty: pathologists viewpoint.
    Melanoma Res. 2023 Jun 13. doi: 10.1097/CMR.0000000000000909.
    PubMed     Abstract available


  96. KISISTOK J, Christensen DS, Rasmussen MH, Duval L, et al
    Analysis of circulating tumor DNA during checkpoint inhibition in metastatic melanoma using a tumor-agnostic panel.
    Melanoma Res. 2023 Jun 12. doi: 10.1097/CMR.0000000000000903.
    PubMed     Abstract available


  97. GARCIA-PEREZ O, Melgar-Vilaplana L, Sifaoui I, Garcia-Bello MA, et al
    Expression of angiogenic and lymphangiogenic genes in primary cutaneous melanoma: relationship with angiolymphatic invasion and disease-free survival.
    Melanoma Res. 2023 Jun 12. doi: 10.1097/CMR.0000000000000904.
    PubMed     Abstract available


  98. AMARA SV, Grbic N, Melson G, Brem CE, et al
    Assessment of lipid and pigment content in suspicious melanocytic lesions to improve melanoma detection.
    Melanoma Res. 2023 Jun 5. doi: 10.1097/CMR.0000000000000902.
    PubMed     Abstract available


  99. CHERSI F, Conforti C, Zalaudek I, Bazzacco G, et al
    Clinical and dermoscopical presentation of nivolumab-induced pemphigoid in a metastatic melanoma patient.
    Melanoma Res. 2023;33:262-263.
    PubMed    


    May 2023
  100. AGNILA DRL, Huda TI, Eakins RA, Patel DN, et al
    Chemical features of melanoma tumor resident TRG CDR3s associated with better survival probabilities.
    Melanoma Res. 2023 May 23. doi: 10.1097/CMR.0000000000000899.
    PubMed     Abstract available


  101. SHELLENBERGER RA, Gowda S, Kurn H, Albright J, et al
    Vitamin D insufficiency and serum levels related to the incidence and stage of cutaneous melanoma: a systematic review and meta-analysis.
    Melanoma Res. 2023 May 18. doi: 10.1097/CMR.0000000000000897.
    PubMed     Abstract available


  102. PHAM JP, On L, Ardolino L, Hurwitz J, et al
    Efficacy of immune checkpoint inhibition in metastatic uveal melanoma: a systematic review and meta-analysis.
    Melanoma Res. 2023 May 18. doi: 10.1097/CMR.0000000000000900.
    PubMed     Abstract available


  103. YOO H, Park S, Kim SW
    Nodular type predominance of head and neck cutaneous malignant melanoma in Asian populations leads to poor outcome and low survival.
    Melanoma Res. 2023 May 18. doi: 10.1097/CMR.0000000000000901.
    PubMed     Abstract available


  104. MATTAVELLI I, Patuzzo R, Galeone C, Pelucchi C, et al
    Potential risk factors, clinicopathological features and determinants of survival for multiple primary melanoma patients compared to single primary melanoma: a large single-center Italian study.
    Melanoma Res. 2023 May 8. doi: 10.1097/CMR.0000000000000898.
    PubMed     Abstract available


  105. OGATA D, Nishio S, Hatta N, Kaji T, et al
    Clinicopathological demographics of malignant melanomas of the vulva and vagina in Japan.
    Melanoma Res. 2023 May 8. doi: 10.1097/CMR.0000000000000894.
    PubMed     Abstract available


    April 2023
  106. DIRVEN I, Vander Mijnsbrugge AS, Mignon S, Tijtgat J, et al
    Auto-immune hemolytic anemia and hemophagocytic lymphohistiocytosis as immune-related adverse event in patients with metastatic melanoma and concurrent chronic lymphocytic leukemia: a case series and literature review.
    Melanoma Res. 2023 Apr 28. doi: 10.1097/CMR.0000000000000895.
    PubMed     Abstract available


  107. WONG CK, Dite GS, Spaeth E, Murphy NM, et al
    Melanoma risk prediction based on a polygenic risk score and clinical risk factors.
    Melanoma Res. 2023 Apr 24. doi: 10.1097/CMR.0000000000000896.
    PubMed     Abstract available


  108. MOHAMMADI A, Najafi S, Amini M, Baradaran B, et al
    B7H6 silencing increases chemosensitivity to dacarbazine and suppresses cell survival and migration in cutaneous melanoma.
    Melanoma Res. 2023 Apr 12. doi: 10.1097/CMR.0000000000000890.
    PubMed     Abstract available


  109. STATHAKI MI, Kapsoritakis N, Michelakis D, Anagnostopoulou E, et al
    The impact of sentinel lymph node mapping with hybrid single photon emission computed tomography/computed tomography in patients with melanoma. Comparison to planar radioisotopic lymphoscintigraphy.
    Melanoma Res. 2023 Apr 12. doi: 10.1097/CMR.0000000000000893.
    PubMed     Abstract available


  110. BRUNSGAARD EK, Bowles TL, Asare EA, Grossmann K, et al
    Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma.
    Melanoma Res. 2023 Apr 5. doi: 10.1097/CMR.0000000000000892.
    PubMed     Abstract available


  111. CYBULSKA-STOPA B, Piejko K, Ostaszewski K, Dziura R, et al
    Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment.
    Melanoma Res. 2023 Apr 3. doi: 10.1097/CMR.0000000000000885.
    PubMed     Abstract available


  112. LE GOUBEY JB, Sassier M, Nakouri I, De Pontville M, et al
    Recurrent hemophagocytic lymphohistiocytosis in advanced melanoma treated with two different BRAF/MEK-inhibitor regimens.
    Melanoma Res. 2023;33:159-161.
    PubMed    


  113. FORTMAN D, Avellan MGP, Hurd D, Schwartz M, et al
    Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients.
    Melanoma Res. 2023;33:136-148.
    PubMed     Abstract available


  114. INGEN-HOUSZ-ORO S, Milpied B, Bensaid B, Elshot Y, et al
    Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases.
    Melanoma Res. 2023;33:155-158.
    PubMed     Abstract available


    March 2023
  115. MANZANO JL, Martin-Liberal J, Fernandez-Morales LA, Benitez G, et al
    Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study.
    Melanoma Res. 2023 Mar 28. doi: 10.1097/CMR.0000000000000888.
    PubMed     Abstract available


  116. VUILLAMY C, Arnault JP, Fumery M, Mortier L, et al
    Clostridium difficile infection and immune checkpoint inhibitor-induced colitis in melanoma: 18 cases and a review of the literature.
    Melanoma Res. 2023 Mar 27. doi: 10.1097/CMR.0000000000000878.
    PubMed     Abstract available


  117. YANG H, Zhou J, Li D, Zhou S, et al
    The inhibitory role of microRNA-141-3p in human cutaneous melanoma growth and metastasis through the fibroblast growth factor 13-mediated mitogen-activated protein kinase axis.
    Melanoma Res. 2023 Mar 21. doi: 10.1097/CMR.0000000000000873.
    PubMed     Abstract available


  118. BOILEAU M, Templier C, Massip E, Dehoux C, et al
    Description of supportive care and feasibility of physical exercise program to improve quality of life in advanced melanoma patients.
    Melanoma Res. 2023 Mar 17. doi: 10.1097/CMR.0000000000000889.
    PubMed     Abstract available


  119. PIGNE T, Levy M, Ducharme O, Dutriaux C, et al
    Real-life use of trametinib after immunotherapy failure in BRAF wild-type advanced melanoma.
    Melanoma Res. 2023 Mar 15. doi: 10.1097/CMR.0000000000000884.
    PubMed     Abstract available


  120. BOILEAU M, Descarpentries C, Delzenne G, Trentesaux V, et al
    Clinical response under MEK inhibitor alone in metastatic melanoma with a novel fusion involving the RAF1 gene.
    Melanoma Res. 2023 Mar 3. doi: 10.1097/CMR.0000000000000882.
    PubMed     Abstract available


  121. JASSO-SOSA VY, Lino-Silva LS, Escobar-Jimenez MG, Galvan-Bustillos JR, et al
    Prognosis of polypoid melanoma: a comparative study with non-polypoid melanomas.
    Melanoma Res. 2023 Mar 3. doi: 10.1097/CMR.0000000000000886.
    PubMed     Abstract available


  122. BERBERICH C, Mustafa M, Zhuwu Y, Gaa J, et al
    The influence of metastatic patterns and tumor load on therapeutic efficacy of immunotherapy in patients with metastatic melanoma as determined by quantitative PET-parameters using [18F]-fluorodeoxyglucose PET/computed tomography.
    Melanoma Res. 2023 Mar 3. doi: 10.1097/CMR.0000000000000883.
    PubMed     Abstract available


    February 2023
  123. KOMULAINEN J, Siiskonen H, Haimakainen S, Kanasuo E, et al
    Patients with a history of atopy have fewer cutaneous melanomas than those without atopy: a cross-sectional study in 496 patients at risk of skin cancers.
    Melanoma Res. 2023 Feb 28:e000887. doi: 10.1097/CMR.0000000000000887.
    PubMed     Abstract available


  124. GORLOV IP, Conway K, Edmiston SN, Parrish EA, et al
    Methylation of nonessential genes in cutaneous melanoma - Rule Out hypothesis.
    Melanoma Res. 2023 Feb 20:e000881. doi: 10.1097/CMR.0000000000000881.
    PubMed     Abstract available


  125. JANSSEN L, Van Kelst S, De Smedt J, Terrasson J, et al
    Preoperative assessment of cutaneous melanoma thickness by multispectral dermoscopy.
    Melanoma Res. 2023;33:84-86.
    PubMed     Abstract available


  126. HUO CW, Gunadasa I, Gkolia P, Shackleton M, et al
    Immune-related adverse events are associated with therapeutic efficacy of immunotherapy in patients with melanoma brain metastases.
    Melanoma Res. 2023;33:58-65.
    PubMed     Abstract available


  127. BETOF WARNER A, Tarhini A, Kang B, Nakasato A, et al
    Real-world outcomes of different lines and sequences of treatment in BRAF-positive advanced melanoma patients.
    Melanoma Res. 2023;33:38-49.
    PubMed     Abstract available


  128. LI C, Ye Z, Wang Y, Wang G, et al
    High expression of GRB2 associated binding protein 3 mRNA predicts positive prognosis in melanoma.
    Melanoma Res. 2023;33:27-37.
    PubMed     Abstract available


  129. RAO D, Lacroix R, Rooker A, Gomes T, et al
    MeVa2.1.dOVA and MeVa2.2.dOVA: two novel BRAFV600E-driven mouse melanoma cell lines to study tumor immune resistance.
    Melanoma Res. 2023;33:12-26.
    PubMed     Abstract available


  130. ZAKRIA D, Brownstone N, Han J, Owji S, et al
    Electrical impedance spectroscopy significantly enhances correct biopsy choice for pigmented skin lesions beyond clinical evaluation and dermoscopy.
    Melanoma Res. 2023;33:80-83.
    PubMed     Abstract available


  131. HOFFMANN F, Frohlich A, Sirokay J, de Vos L, et al
    DNA methylation of GITR, OX40, 4-1BB, CD27, and CD40 correlates with BAP1 aberrancy and prognosis in uveal melanoma.
    Melanoma Res. 2023 Feb 1. doi: 10.1097/CMR.0000000000000879.
    PubMed     Abstract available


    January 2023
  132. KOWALIK A, Karpinski P, Markiewicz A, Orlowska-Heitzman J, et al
    Molecular profiling of primary uveal melanoma: results of a Polish cohort.
    Melanoma Res. 2023 Jan 30. doi: 10.1097/CMR.0000000000000874.
    PubMed     Abstract available


  133. PINTO C, Aluai-Cunha C, Santos A
    The human and animals' malignant melanoma: comparative tumor models and the role of microbiome in dogs and humans.
    Melanoma Res. 2023 Jan 20:CMR.0000000000000880.
    PubMed     Abstract available


    December 2022
  134. KANASUO E, Siiskonen H, Haimakainen S, Komulainen J, et al
    Regular use of vitamin D supplement is associated with fewer melanoma cases compared to non-use: a cross-sectional study in 498 adult subjects at risk of skin cancers.
    Melanoma Res. 2022 Dec 28:CMR.0000000000000870.
    PubMed     Abstract available


  135. GAJANAN K, Daga K, Mullan D, Kosutic D, et al
    New technique for in-continuity axillary and supraclavicular lymphadenectomy for advanced metastatic melanoma using intraoperative image guidance: a case report.
    Melanoma Res. 2022 Dec 28. doi: 10.1097/CMR.0000000000000868.
    PubMed     Abstract available


  136. GARGIULO L, Ibba L, Valenti M, Costanzo A, et al
    Pembrolizumab-induced plaque psoriasis successfully treated with risankizumab in a patient with stage IV cutaneous melanoma.
    Melanoma Res. 2022 Dec 27:CMR.0000000000000875.
    PubMed     Abstract available



  137. Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis: Erratum.
    Melanoma Res. 2022;32:492.
    PubMed    


  138. BORGOGNONI L, Crocetti E, Sestini S, Brandani P, et al
    The importance of mitosis >/=2 in selecting patients with T1 cutaneous melanomas for sentinel lymph node biopsy.
    Melanoma Res. 2022;32:469-476.
    PubMed     Abstract available


  139. SMITH JL, Menzies AM, Cohen JV, Mut-Lloret M, et al
    Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series.
    Melanoma Res. 2022;32:451-459.
    PubMed     Abstract available


    November 2022
  140. FRANKE V, Stahlie EHA, Klop WMC, Zuur CL, et al
    Talimogene laherparepvec monotherapy for head and neck melanoma patients.
    Melanoma Res. 2022 Nov 29. doi: 10.1097/CMR.0000000000000866.
    PubMed     Abstract available


  141. TRIVEDI DB, Aldulaimi N, Karydis I, Wheater M, et al
    Liver resection for metastatic uveal melanoma: experience from a supra-regional centre and review of literature.
    Melanoma Res. 2022 Nov 21. doi: 10.1097/CMR.0000000000000867.
    PubMed     Abstract available


  142. KARTOLO A, Tong J, Yeung C, Kuksis M, et al
    Survivals following discontinuation of PD-1 inhibitor treatment in advanced melanoma patients.
    Melanoma Res. 2022 Nov 16. pii: 00008390-990000000-00046.
    PubMed     Abstract available


    October 2022
  143. RAMOS R, Cabre E, Vinyals A, Lorenzo D, et al
    Orthotopic murine xenograft model of uveal melanoma with spontaneous liver metastasis.
    Melanoma Res. 2022 Oct 28. pii: 00008390-990000000-00043.
    PubMed     Abstract available


  144. SHUI IM, Scherrer E, Frederickson A, Li JW, et al
    Resistance to anti-PD1 therapies in patients with advanced melanoma: systematic literature review and application of the Society for Immunotherapy of Cancer immunotherapy resistance taskforce anti-PD1 resistance definitions.
    Melanoma Res. 2022 Oct 7. pii: 00008390-990000000-00037.
    PubMed     Abstract available


  145. CAVALLO F, Roccuzzo G, Merli M, Avallone G, et al
    BRCA1-associated protein 1 c.368delG mutation leads to the development of multiple BAPomas and cutaneous melanomas: a novel pathogenic variant in BRCA1-associated protein tumor predisposition syndrome.
    Melanoma Res. 2022;32:390-392.
    PubMed    


  146. BRUGUES A, Ribero S, Pastorino C, Iglesias P, et al
    Challenging pigmented lesions in melanoma patients during checkpoint-inhibitors therapy.
    Melanoma Res. 2022;32:388-390.
    PubMed    


    September 2022
  147. EDMONDS NL, Flores SE, Mahmutovic A, Young SJ, et al
    CD103 and periplakin are potential biomarkers for response of metastatic melanoma to pembrolizumab.
    Melanoma Res. 2022 Sep 28. pii: 00008390-990000000-00041.
    PubMed     Abstract available


  148. FADADU RP, Wei ML
    Ultraviolet A radiation exposure and melanoma: a review.
    Melanoma Res. 2022 Sep 20. pii: 00008390-990000000-00039.
    PubMed     Abstract available


  149. MENNENS F, Van Herck Y, Sciot R, Bempt IV, et al
    Melanoma cell plasticity poses diagnostic challenges: a case series.
    Melanoma Res. 2022 Sep 20. pii: 00008390-990000000-00038.
    PubMed     Abstract available


  150. TEJEDOR I, Tedbirt B, Carvalho P, Duval-Modeste AB, et al
    Successful use of rituximab for refractory hemophagocytic lymphohistiocytosis in a melanoma patient treated with targeted therapy.
    Melanoma Res. 2022 Sep 20. pii: 00008390-990000000-00036.
    PubMed     Abstract available


  151. SCHILLER T, Vaisbuch E, Zornitzki T, Kirzhner A, et al
    Adrenal metastatic melanoma first identified during pregnancy: a diagnostic challenge.
    Melanoma Res. 2022 Sep 13. pii: 00008390-990000000-00035.
    PubMed     Abstract available


  152. YIN L, Liu X, Wu J, Yang J, et al
    LS-007 inhibits melanoma growth via inducing apoptosis and cell cycle arrest and regulating macrophage polarization.
    Melanoma Res. 2022 Sep 9. pii: 00008390-990000000-00034.
    PubMed     Abstract available


    August 2022
  153. COMITO F, Aprile M, Pagani R, Siepe G, et al
    Clinical characteristics and treatment outcomes of non-V600 E/K BRAF mutant melanoma patients: a single-institution experience.
    Melanoma Res. 2022 Aug 29. pii: 00008390-990000000-00033.
    PubMed     Abstract available


  154. ZHENG YJ, Ho W, Sanlorenzo M, Vujic I, et al
    Melanoma risk during immunomodulating treatment.
    Melanoma Res. 2022 Aug 22. pii: 00008390-990000000-00032.
    PubMed     Abstract available


  155. GRACIA-DARDER I, Carrera C, Alamon-Reig F, Puig S, et al
    Vitamin D deficiency in melanoma patients is associated with worse overall survival: a retrospective cohort study.
    Melanoma Res. 2022 Aug 17. pii: 00008390-990000000-00030.
    PubMed     Abstract available


  156. BROWNSTONE N, Marson JW, Zakria D, Farberg A, et al
    Variance from published guidelines and changes in temporal trends in the management of cutaneous malignant melanoma: a 5-year update.
    Melanoma Res. 2022 Aug 17. pii: 00008390-990000000-00031.
    PubMed     Abstract available


  157. LASOCKI A, McArthur GA
    Correlation of MRI signal characteristics of intracranial melanoma metastases with BRAF mutation status.
    Melanoma Res. 2022 Aug 17. pii: 00008390-990000000-00029.
    PubMed     Abstract available


    July 2022
  158. MANGANA J, Zihler D, Bossart S, Bronnimann D, et al
    Treatment reality of patients with BRAF-mutant advanced/metastatic melanoma in Switzerland in the era of choice.
    Melanoma Res. 2022 Jul 20. pii: 00008390-990000000-00028.
    PubMed     Abstract available


  159. BUJA A, Rugge M, De Luca G, Zorzi M, et al
    Clinical performance indicators for monitoring the management of cutaneous melanoma: a population-based perspective.
    Melanoma Res. 2022 Jul 19. pii: 00008390-990000000-00027.
    PubMed     Abstract available


  160. FILIPPI F, Serra N, Vigano P, Boeri L, et al
    Fertility preservation for patients with melanoma.
    Melanoma Res. 2022 Jul 19. pii: 00008390-990000000-00025.
    PubMed     Abstract available


  161. OSTOJIC N, Radevic T, Kandolf Sekulovic L, Djordjevic B, et al
    Polymorphisms in toll-like receptor 3 and 4 genes as prognostic and outcome biomarkers in melanoma patients.
    Melanoma Res. 2022 Jul 19. pii: 00008390-990000000-00026.
    PubMed     Abstract available


  162. KLEE G, Hagelstein V, Kurzhals JK, Zillikens D, et al
    Dacarbazine in the management of metastatic melanoma in the era of immune checkpoint therapy: a valid option or obsolete?
    Melanoma Res. 2022 Jul 19. pii: 00008390-990000000-00024.
    PubMed     Abstract available


  163. LINO-SILVA LS, Zepeda-Najar C, Caro-Sanchez CH, Herrera-Gomez A, et al
    Prognostic significance of tumor budding in melanoma.
    Melanoma Res. 2022 Jul 1. pii: 00008390-990000000-00023.
    PubMed     Abstract available


    June 2022
  164. GONZALEZ-BARRALLO I, Castellon Rubio VE, Medina J, Espana S, et al
    Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL).
    Melanoma Res. 2022 Jun 27. pii: 00008390-990000000-00022.
    PubMed     Abstract available


  165. TASKAYNATAN H, Gunenc D, On S, Mizrak A, et al
    Immunotherapy-induced granulomatous reaction in patients with melanoma.
    Melanoma Res. 2022 Jun 23. pii: 00008390-990000000-00021.
    PubMed     Abstract available


  166. YU IS, Wee K, Williamson L, Titmuss E, et al
    Exceptional response to combination ipilimumab and nivolumab in metastatic uveal melanoma: Insights from genomic analysis.
    Melanoma Res. 2022 Jun 17. pii: 00008390-990000000-00020.
    PubMed     Abstract available


  167. SIZOVA M, Camacho V, Sampedro F, Sabate-Llobera A, et al
    Brain metabolic changes in patients with disseminated malignant melanoma under immunotherapy.
    Melanoma Res. 2022 Jun 15. pii: 00008390-990000000-00019.
    PubMed     Abstract available


  168. WEBER JS, Levinson BA, Laino AS, Pavlick AC, et al
    Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma.
    Melanoma Res. 2022 Jun 9. pii: 00008390-990000000-00018.
    PubMed     Abstract available


  169. ISMAIL RK, Suijkerbuijk KPM, de Boer A, van Dartel M, et al
    Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors.
    Melanoma Res. 2022 Jun 6. pii: 00008390-990000000-00017.
    PubMed     Abstract available


  170. INGEN-HOUSZ-ORO S, Milpied B, Badrignans M, Carrera C, et al
    Severe blistering eruptions induced by immune checkpoint inhibitors: a multicentre international study of 32 cases.
    Melanoma Res. 2022;32:205-210.
    PubMed     Abstract available


    May 2022
  171. RODRIGUEZ CASTELLS M, Galisteo Lencastre Veiga C, Fernandez-Morales LA, Ejarque Martinez C, et al
    Immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies, in a patient with melanoma treated with BRAF/MEK inhibitors.
    Melanoma Res. 2022 May 30. pii: 00008390-990000000-00016.
    PubMed     Abstract available


  172. MEYER N, Perol D, Duval-Modeste AB, El Adaoui L, et al
    Survival in adult patients with BRAFV600 mutation-positive advanced melanoma: a noninterventional ambispective study of patients with cobimetinib combined with vemurafenib during the French early access program: MELANIS study.
    Melanoma Res. 2022 May 27. pii: 00008390-990000000-00015.
    PubMed     Abstract available


  173. MADISON CJ, Heinrich MC, Thompson RF, Yu WY, et al
    Statin use is associated with improved overall survival in patients with melanoma.
    Melanoma Res. 2022 May 13. pii: 00008390-990000000-00012.
    PubMed     Abstract available


  174. LI AT, Miin Yip J, Choksi H, London K, et al
    Lack of association between anatomical sites of scalp melanomas and brain metastases does not support direct vascular spread.
    Melanoma Res. 2022 May 13. pii: 00008390-990000000-00013.
    PubMed     Abstract available


  175. DIKA E, Lambertini M, Lauriola M, Veronesi G, et al
    Female melanoma and estrogen receptors expression: an immunohistochemical pilot study.
    Melanoma Res. 2022 May 13. pii: 00008390-990000000-00010.
    PubMed     Abstract available


  176. SEYED JAFARI SM, Mazinani M, Beutler-Minth V, Lamos C, et al
    Noncontrast-enhanced 3-Tesla MRI using surface coil as a complementary test for assessment of distribution and depth of locoregional cutaneous metastases of malignant melanoma.
    Melanoma Res. 2022 May 13. pii: 00008390-990000000-00011.
    PubMed     Abstract available


  177. HANNARICI Z, Yilmaz A, Buyukbayram ME, Tekin SB, et al
    Reply to John L. Frater's letter to the editor entitled Use of laboratory hematology data in melanoma research: comments on 'A novel prognostic biomarker for cutaneous malignant melanoma: red cell distribution width (RDW) to lymphocyte ratio'.
    Melanoma Res. 2022 May 13. pii: 00008390-990000000-00014.
    PubMed    


  178. WOLFE Z, Friedland JC, Ginn S, Blackham A, et al
    Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma.
    Melanoma Res. 2022 May 12. pii: 00008390-990000000-00009.
    PubMed     Abstract available


    April 2022
  179. MULDER EEAP, Damman J, Verver D, van der Veldt AAM, et al
    Histopathological and immunological spectrum in response evaluation of talimogene laherparepvec treatment and correlation with durable response in patients with cutaneous melanoma.
    Melanoma Res. 2022 Apr 21. pii: 00008390-990000000-00008.
    PubMed     Abstract available


  180. SCHMELTER V, Hofmann T, Schneider F, Weber C, et al
    Robotic CyberKnife radiosurgery for small choroidal melanomas.
    Melanoma Res. 2022 Apr 8. pii: 00008390-990000000-00007.
    PubMed     Abstract available


  181. FRATER JL
    Use of laboratory hematology data in melanoma research: comments on "A novel prognostic biomarker for cutaneous malignant melanoma: red cell distribution width (RDW) to lymphocyte ratio" Melanoma Res 2021; 31:566-574.
    Melanoma Res. 2022;32:136.
    PubMed    


  182. O'DAY R, Grantham M, Thaung C, Szlosarek P, et al
    Tetrasomy of chromosomes 3 and 8 in a young male with choroidal melanoma.
    Melanoma Res. 2022;32:134-135.
    PubMed    


  183. GAMBICHLER T, Susok L
    Uncomplicated pregnancy and delivery under ongoing nivolumab therapy for metastatic melanoma.
    Melanoma Res. 2022;32:132-133.
    PubMed    


  184. FARRELL J, Stewart TJ, Rosen R
    Study of clinical characteristics and risk factors for amelanotic/hypomelanotic melanoma in an Australian cohort.
    Melanoma Res. 2022;32:130-131.
    PubMed    


  185. MIECZKOWSKA K, Jacob J, Paoluzzi L, Papalezova KT, et al
    Documenting the histologic response of metastatic melanoma to combination therapy with BRAF and MEK inhibitors.
    Melanoma Res. 2022;32:128-129.
    PubMed    


  186. KROMER C, Vlahova LD, Julius K, Schnabel V, et al
    Response of metastatic melanoma with a rare BRAF V600K mutation to dabrafenib and trametinib.
    Melanoma Res. 2022;32:124-127.
    PubMed    


  187. MODI S, Gibson T, Vigneswaran G, Patel S, et al
    Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma.
    Melanoma Res. 2022;32:103-111.
    PubMed     Abstract available


  188. WISCO OJ, Marson JW, Litchman GH, Brownstone N, et al
    Improved cutaneous melanoma survival stratification through integration of 31-gene expression profile testing with the American Joint Committee on Cancer 8th Edition Staging.
    Melanoma Res. 2022;32:98-102.
    PubMed     Abstract available


  189. WACH MM, Subjeck JR, Wang XY, Repasky E, et al
    Recombinant human Hsp110-gp100 chaperone complex vaccine is nontoxic and induces response in advanced stage melanoma patients.
    Melanoma Res. 2022;32:88-97.
    PubMed     Abstract available


  190. HILL MV, Vidri RJ, Deng M, Handorf E, et al
    Real-world frequency of BRAF testing and utilization of therapies in patients with advanced melanoma.
    Melanoma Res. 2022;32:79-87.
    PubMed     Abstract available


  191. YIN G, Guo W, Huang Z, Chen X, et al
    Efficacy of radiotherapy combined with immune checkpoint inhibitors in patients with melanoma: a systemic review and meta-analysis.
    Melanoma Res. 2022;32:71-78.
    PubMed     Abstract available


    March 2022
  192. AWADA G, Schwarze JK, Tijtgat J, Fasolino G, et al
    A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors.
    Melanoma Res. 2022 Mar 29. pii: 00008390-990000000-00001.
    PubMed     Abstract available


  193. WANG CY, Zoungas S, Voskoboynik M, Mar V, et al
    Cardiovascular disease and malignant melanoma.
    Melanoma Res. 2022 Mar 29. pii: 00008390-990000000-00004.
    PubMed     Abstract available


  194. YANO M, Nasu K, Yasuda M, Katoh T, et al
    Clinicopathological features and programmed death-ligand 1 immunohistochemical expression in a multicenter cohort of uterine and ovarian melanomas: a retrospective study in Japan (KCOG-G1701s).
    Melanoma Res. 2022 Mar 29. pii: 00008390-990000000-00002.
    PubMed     Abstract available


  195. LAUWYCK J, Schreuer M, Meric de Bellefon L, Van Erps J, et al
    Severe treatment-induced inflammatory polyarthritis in advanced melanoma patients: 2 case reports.
    Melanoma Res. 2022 Mar 29. pii: 00008390-990000000-00003.
    PubMed     Abstract available


  196. FU XL, Feng LP, Yu HR, Du L, et al
    Efficacy and safety of angiogenesis inhibitors in melanoma: a meta-analysis of seven randomized controlled trials.
    Melanoma Res. 2022 Mar 29. pii: 00008390-990000000-00005.
    PubMed     Abstract available


  197. PEDERSEN S, Moller S, Donia M, Persson GF, et al
    Real-world data on melanoma brain metastases and survival outcome.
    Melanoma Res. 2022 Mar 7. pii: 00008390-900000000-98978.
    PubMed     Abstract available


  198. XU J, Ou R, Nie G, Wen J, et al
    LINC01063 functions as an oncogene in melanoma through regulation of miR-5194-mediated SOX12 expression.
    Melanoma Res. 2022 Mar 7. pii: 00008390-900000000-98977.
    PubMed     Abstract available


  199. MCCANN B, Higgins M, Kok DL, Hong W, et al
    Long-term control of melanoma adrenal metastasis treated with radiotherapy.
    Melanoma Res. 2022 Mar 7. pii: 00008390-900000000-98976.
    PubMed     Abstract available


    February 2022
  200. HOTZ MJ, O'Halloran EA, Hill MV, Hayden K, et al
    Tumor mutational burden and somatic mutation status to predict disease recurrence in advanced melanoma.
    Melanoma Res. 2022 Feb 24. pii: 00008390-900000000-98979.
    PubMed     Abstract available


  201. ZHOU L, Yang Y, Si L, Chi Z, et al
    Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy.
    Melanoma Res. 2022 Feb 20. pii: 00008390-900000000-98980.
    PubMed     Abstract available


  202. STECKLER AM, Francis JH, Shoushtari AN, Abramson DH, et al
    Uveal melanoma metastatic at initial diagnosis: a case series.
    Melanoma Res. 2022 Feb 11. pii: 00008390-900000000-98981.
    PubMed     Abstract available


  203. DUNJIC M, Lukic N, Djordjevic B, Uzelac B, et al
    GLI-1 polymorphisms of Hedgehog pathway as novel risk and prognostic biomarkers in melanoma patients.
    Melanoma Res. 2022;32:11-17.
    PubMed     Abstract available


  204. LEE J, Jin YJ, Lee MS, Lee H, et al
    Macrophage inhibitory cytokine-1 produced by melanoma cells contributes to melanoma tumor growth and metastasis in vivo by enhancing tumor vascularization.
    Melanoma Res. 2022;32:1-10.
    PubMed     Abstract available


  205. KIM YH, Kim Y, Park TJ, Kang HY, et al
    Ponatinib-induced eruptive nevi and melanocytic proliferation.
    Melanoma Res. 2022;32:59-62.
    PubMed     Abstract available


    December 2021
  206. SUN S, Shi R, Xu L, Sun F, et al
    Identification of heterogeneity and prognostic key genes associated with uveal melanoma using single-cell RNA-sequencing technology.
    Melanoma Res. 2021 Dec 3. pii: 00008390-900000000-98987.
    PubMed     Abstract available


  207. JANOWSKA A, Oranges T, Iannone M, Davini G, et al
    Ultra-high-frequency ultrasound monitoring of melanomas arising in congenital melanocytic nevi: a case series.
    Melanoma Res. 2021;31:561-565.
    PubMed     Abstract available


  208. YE JY, Yu C, Husman T, Chen B, et al
    Novel strategy for applying hierarchical density-based spatial clustering of applications with noise towards spectroscopic analysis and detection of melanocytic lesions.
    Melanoma Res. 2021;31:526-532.
    PubMed     Abstract available


    November 2021
  209. CAKIR OO, Pozzi E, Castiglione F, Freeman A, et al
    Clinical features, molecular characteristics and surgical management of primary penile mucosal melanoma based on the European Association of Urology Penile Cancer Guidelines.
    Melanoma Res. 2021 Nov 24. pii: 00008390-900000000-98989.
    PubMed     Abstract available


  210. DAVIDSON TM, Markovic SN, Dimou A
    The immunologic balance: three cases of rituximab-associated melanoma.
    Melanoma Res. 2021 Nov 15. pii: 00008390-900000000-98990.
    PubMed     Abstract available


  211. SAH VR, Karlsson J, Jespersen H, Lindberg MF, et al
    Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma.
    Melanoma Res. 2021 Nov 5. pii: 00008390-900000000-98991.
    PubMed     Abstract available


  212. DE GIORGI V, Gemignani A, Scarfi F, Trane L, et al
    Eruptive melanocytic nevi in a patient with amelanotic melanoma: a paraneoplastic phenomenon?
    Melanoma Res. 2021 Nov 1. pii: 00008390-900000000-98993.
    PubMed     Abstract available


  213. JAN WILLEM RAUWERDINK D, van Persijn van Meerten E, van der Hage J, Kapiteijn E, et al
    Management of heterogeneous tumor response patterns to immunotherapy in patients with metastatic melanoma.
    Melanoma Res. 2021 Nov 1. pii: 00008390-900000000-98992.
    PubMed     Abstract available


    October 2021
  214. PARIETTI M, Marra E, Ribero S, Abate SO, et al
    Leptomeningeal dissemination as a first sign of progression in metastatic melanoma: a diagnostic lesson.
    Melanoma Res. 2021 Oct 22. pii: 00008390-900000000-98994.
    PubMed     Abstract available


  215. MOGLIA A, Cerri A, Moglia A, Berchiolli R, et al
    Machine learning for the identification of decision boundaries during the transition from radial to vertical growth phase superficial spreading melanomas.
    Melanoma Res. 2021 Oct 21. pii: 00008390-900000000-98995.
    PubMed     Abstract available


  216. MANTIA CM, Werner L, Stwalley B, Ritchings C, et al
    Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors.
    Melanoma Res. 2021 Oct 20. pii: 00008390-900000000-98997.
    PubMed     Abstract available


  217. GARGIULO L, Chiara Tronconi M, Grimaudo MS, Pavia G, et al
    Connective tissue panniculitis and vitiligo in a with patient stage IV melanoma achieving complete response to dabrafenib and trametinib combination therapy.
    Melanoma Res. 2021 Oct 5. pii: 00008390-900000000-98999.
    PubMed     Abstract available


  218. JANOWSKA A, Oranges T, Iannone M, Romanelli M, et al
    Seborrheic keratosis-like melanoma: a diagnostic challenge.
    Melanoma Res. 2021;31:407-412.
    PubMed     Abstract available


  219. TULOKAS SKA, Kohtamaki LM, Makela SP, Juteau S, et al
    Isolated limb perfusion with melphalan as treatment for regionally advanced melanoma of the limbs: results of 60 patients treated in Finland during 2007-2018.
    Melanoma Res. 2021;31:456-463.
    PubMed     Abstract available


    September 2021
  220. HANNARICI Z, Yilmaz A, Buyukbayram ME, Tekin SB, et al
    A novel prognostic biomarker for cutaneous malignant melanoma: red cell distribution width (RDW) to lymphocyte ratio.
    Melanoma Res. 2021 Sep 23. pii: 00008390-900000000-99001.
    PubMed     Abstract available


  221. FIDANZI C, Manzo Margiotta F, Spinelli C, Janowska A, et al
    Risk factors in pediatric melanoma: a retrospective study of 39 cases.
    Melanoma Res. 2021 Sep 23. pii: 00008390-900000000-99000.
    PubMed     Abstract available


  222. AMAGAI R, Muto Y, Kato H, Matsushita S, et al
    Retrospective analysis of adjuvant therapy using dabrafenib plus trametinib in Japanese patients with advanced melanoma: analysis of 36 cases.
    Melanoma Res. 2021 Sep 13. pii: 00008390-900000000-99006.
    PubMed     Abstract available


  223. FONSECA M, Soares R, Coelho P
    Lower melanoma pulmonary metastatic burden in obese mice: role of FGF-21.
    Melanoma Res. 2021 Sep 13. pii: 00008390-900000000-99005.
    PubMed     Abstract available


  224. LAN S, Cui Z, Yin Q, Liu Z, et al
    Prospective study of clinical characteristics of melanoma patients with retinopathy caused by a high-dose interferon alpha-2b.
    Melanoma Res. 2021 Sep 13. pii: 00008390-900000000-99004.
    PubMed     Abstract available


  225. CHEN M, Li Q, Chen W, Bi J, et al
    Diagnostic and prognostic value of Beclin 1 expression in melanoma: a meta-analysis.
    Melanoma Res. 2021 Sep 7. pii: 00008390-900000000-99008.
    PubMed     Abstract available


  226. SHI CJ, Xu SM, Han Y, Zhou R, et al
    Targeting cyclin-dependent kinase 4/6 as a therapeutic approach for mucosal melanoma.
    Melanoma Res. 2021 Sep 3. pii: 00008390-900000000-99009.
    PubMed     Abstract available


    August 2021
  227. AVALLONE G, Astrua C, Fava P, Tonella L, et al
    Acute appendicitis secondary to desmoplastic melanoma metastasis in immune-checkpoint inhibitors era.
    Melanoma Res. 2021 Aug 27. pii: 00008390-900000000-99010.
    PubMed    


  228. FARINAZZO E, Zelin E, Agozzino M, Papa G, et al
    Regression of nevi, vitiligo-like depigmentation and halo phenomenon may indicate response to immunotherapy and targeted therapy in melanoma.
    Melanoma Res. 2021 Aug 23. pii: 00008390-900000000-99016.
    PubMed     Abstract available


  229. GULIKERS JL, Croes S, Schreurs MJW, Litjens EJR, et al
    Nivolumab exposure in a hemodialysis patient with metastatic melanoma.
    Melanoma Res. 2021 Aug 23. pii: 00008390-900000000-99015.
    PubMed     Abstract available


  230. INDINI A, Costa S, Ierardi AM, Rijavec E, et al
    COVID-19 vaccination mimicking lymph-node progression in a patient with melanoma: a case report.
    Melanoma Res. 2021 Aug 23. pii: 00008390-900000000-99014.
    PubMed     Abstract available


  231. SCHNEIDER S, Alezra E, Yacoub M, Ducharme O, et al
    Aseptic cystitis induced by nivolumab and ipilimumab combination for metastatic melanoma.
    Melanoma Res. 2021 Aug 23. pii: 00008390-900000000-99013.
    PubMed     Abstract available


  232. CHO KK, Cust AE, Foo YM, Long GV, et al
    Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis.
    Melanoma Res. 2021 Aug 23. pii: 00008390-900000000-99012.
    PubMed     Abstract available


  233. SILVA CTX, Saddi VA, Silva KSFE, Sugita DM, et al
    Expression of the cancer stem cell marker OCT4 is associated with worse prognosis and survival in cutaneous melanoma.
    Melanoma Res. 2021 Aug 23. pii: 00008390-900000000-99011.
    PubMed     Abstract available


  234. GE Y, Che X, Gao X, Zhao S, et al
    Combination of radiotherapy and targeted therapy for melanoma brain metastases: a systematic review.
    Melanoma Res. 2021 Aug 17. pii: 00008390-900000000-99017.
    PubMed     Abstract available


  235. CULLEN GD, Finnes HD, Markovic SN, Volcheck GW, et al
    Successful encorafenib desensitization in a patient with recurrent metastatic melanoma.
    Melanoma Res. 2021;31:402-404.
    PubMed     Abstract available


  236. ADAMS AM, Chick RC, Vreeland TJ, Clifton GT, et al
    Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma.
    Melanoma Res. 2021;31:378-388.
    PubMed     Abstract available


  237. XIAO M, Tang N, Yan Y, Li Z, et al
    Knockdown of enhancer of rudimentary homolog expression attenuates proliferation, cell cycle and apoptosis of melanoma cells.
    Melanoma Res. 2021;31:309-318.
    PubMed     Abstract available


  238. PIKKEL YY, Duek OS, Ben Naftali Y, Link Y, et al
    Hidden in plain sight: the (other) danger of COVID-19.
    Melanoma Res. 2021;31:389-392.
    PubMed     Abstract available


    July 2021
  239. KLEE G, Kurzhals J, Hagelstein V, Zillikens D, et al
    Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure.
    Melanoma Res. 2021 Jul 19. pii: 00008390-900000000-99021.
    PubMed     Abstract available


  240. TORRICELLI C, Carron J, Carvalho BF, Macedo LT, et al
    Influence of IL1B (rs16944) and IL1R2 (rs4141134) polymorphisms on aggressiveness and prognosis of cutaneous melanoma.
    Melanoma Res. 2021 Jul 19. pii: 00008390-900000000-99020.
    PubMed     Abstract available


  241. MONDAL SK, Whiteside TL
    Proteomic profiles of melanoma cell-derived exosomes in plasma: discovery of potential biomarkers of melanoma progression.
    Melanoma Res. 2021 Jul 19. pii: 00008390-900000000-99018.
    PubMed     Abstract available


    June 2021
  242. SANGSTER AB, Chang-McDonald B, Patel J, Bockett N, et al
    Expression of cathepsins B and D by cancer stem cells in head and neck metastatic malignant melanoma.
    Melanoma Res. 2021 Jun 10. pii: 00008390-900000000-99027.
    PubMed     Abstract available


  243. MANNING A, Rassie K, Rivalland G
    A case of hyperprolactinaemia in a patient with metastatic melanoma.
    Melanoma Res. 2021;31:277-279.
    PubMed     Abstract available


  244. TIJTGAT J, Schwarze JK, Awada G, Neyns B, et al
    Sarcoid-like reaction in a BRAF V600E-mutated metastatic melanoma patient during treatment with BRAF/MEK-targeted therapy.
    Melanoma Res. 2021;31:272-276.
    PubMed     Abstract available


  245. HOLSTEAD RG, Kartolo BA, Hopman WM, Baetz TD, et al
    Impact of the development of immune related adverse events in metastatic melanoma treated with PD -1 inhibitors.
    Melanoma Res. 2021;31:258-263.
    PubMed     Abstract available


  246. FRELAU A, Jali E, Campillo-Gimenez B, Pracht M, et al
    Prognostic impact of thyroid dysfunctions on progression-free survival in patients with metastatic melanoma treated with anti-PD-1 antibodies.
    Melanoma Res. 2021;31:208-217.
    PubMed     Abstract available


  247. SANCHEZ JN, Subramanian C, Chanda M, Shanguan G, et al
    A novel C-terminal Hsp90 inhibitor KU758 synergizes efficacy in combination with BRAF or MEK inhibitors and targets drug-resistant pathways in BRAF-mutant melanomas.
    Melanoma Res. 2021;31:197-207.
    PubMed     Abstract available


    May 2021
  248. HE H, Qiao B, Guo S, Cui H, et al
    Induction of T helper 17 cell response by interleukin-7 in patients with primary cutaneous melanoma.
    Melanoma Res. 2021 May 28. pii: 00008390-900000000-99031.
    PubMed     Abstract available


  249. KHULLAR K, Hanft S, Mehnert JM, Weiner JP, et al
    Complete response of brainstem metastasis in BRAF-mutated melanoma without stereotactic radiosurgery after initiation of encorafenib and binimetinib.
    Melanoma Res. 2021 May 28. pii: 00008390-900000000-99030.
    PubMed     Abstract available


  250. LAUWYCK J, Beckwee A, Santens A, Schwarze JK, et al
    C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting.
    Melanoma Res. 2021 May 28. pii: 00008390-900000000-99028.
    PubMed     Abstract available


  251. TACAR SY, Selcukbiricik F, Yilmaz M, Erturk K, et al
    Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study.
    Melanoma Res. 2021 May 25. pii: 00008390-900000000-99038.
    PubMed     Abstract available


  252. WILSON T, Taylor H, Winter H, Herbert C, et al
    Sequential immunotherapy in melanoma: is it a realistic alternative to dual immunotherapy?
    Melanoma Res. 2021 May 25. pii: 00008390-900000000-99037.
    PubMed     Abstract available


  253. HARDIE CM, Allouni A, Edwards S, Ahmed N, et al
    PET-CT for staging pT4b melanomas prior to sentinel lymph node biopsy: a 5-year review.
    Melanoma Res. 2021 May 25. pii: 00008390-900000000-99036.
    PubMed     Abstract available


  254. READ RL, Thompson JF
    The role of regional chemotherapy for advanced limb melanoma in the era of potentially effective systemic therapies.
    Melanoma Res. 2021 May 25. pii: 00008390-900000000-99035.
    PubMed     Abstract available


  255. ZHAO Y, Huang C
    The role of osteopontin in the development and metastasis of melanoma.
    Melanoma Res. 2021 May 25. pii: 00008390-900000000-99034.
    PubMed     Abstract available


  256. MALISSEN N, Farvacque G, Duconseil P, Birnbaum DJ, et al
    Surgery of small bowel melanoma metastases in the era of efficient medical therapies: a retrospective cohort study.
    Melanoma Res. 2021 May 25. pii: 00008390-900000000-99033.
    PubMed     Abstract available


  257. YANG LX, Guo HB, Liu SY, Feng HP, et al
    ETS1 promoted cell growth, metastasis and epithelial-mesenchymal transition process in melanoma by regulating miR-16-mediated SOX4 expression.
    Melanoma Res. 2021 May 25. pii: 00008390-900000000-99032.
    PubMed     Abstract available


  258. WU X, Yan J, Yu J, Cheng Z, et al
    Clinical significance of CCNE1 copy number gain in acral melanoma patients.
    Melanoma Res. 2021 May 6. pii: 00008390-900000000-99040.
    PubMed     Abstract available


  259. BONHOURE A, Henry L, Morille M, Aissaoui N, et al
    Melanotransferrin is efficiently sorted on the surface of exosomes secreted by melanoma cells.
    Melanoma Res. 2021 May 6. pii: 00008390-900000000-99039.
    PubMed     Abstract available


    April 2021
  260. TREMBATH DG, Ivanova A, Krauze MT, Kirkwood JM, et al
    Melanoma-specific expression of the tumor suppressor proteins p16 and PTEN is a favorable prognostic factor in established melanoma brain metastases.
    Melanoma Res. 2021 Apr 12. pii: 00008390-900000000-99043.
    PubMed     Abstract available


  261. LEENEMAN B, Blommestein HM, Coupe VMH, Hendriks MP, et al
    Real-world healthcare costs of localized and regionally advanced cutaneous melanoma in the Netherlands.
    Melanoma Res. 2021 Apr 12. pii: 00008390-900000000-99042.
    PubMed     Abstract available


  262. MOSCHOS SJ, Eroglu Z, Khushalani NI, Kendra KL, et al
    Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922).
    Melanoma Res. 2021;31:162-172.
    PubMed     Abstract available


    March 2021
  263. THOMPSON JF, Saw RPM, Dalton JM, Stretch JR, et al
    Treatment of in-transit melanoma metastases using intralesional PV-10.
    Melanoma Res. 2021 Mar 18. pii: 00008390-900000000-99046.
    PubMed     Abstract available


  264. SHAH P, Punekar SR, Pavlick AC
    Response to immune checkpoint inhibitor rechallenge after high-grade immune related adverse events in patients with advanced melanoma.
    Melanoma Res. 2021 Mar 18. pii: 00008390-900000000-99045.
    PubMed     Abstract available


  265. KOHTAMAKI LM, Hernberg M, Jaakkola M, Makela S, et al
    BRAF inhibitor treatment is feasible in the oldest-old advanced melanoma patients.
    Melanoma Res. 2021 Mar 5. pii: 00008390-900000000-99047.
    PubMed     Abstract available


    February 2021
  266. WESTON GK, Jeong HS, Mu EW, Polsky D, et al
    Impact of COVID-19 on melanoma diagnosis.
    Melanoma Res. 2021 Feb 18. pii: 00008390-900000000-99056.
    PubMed    


  267. LEJEUNE FJ, Storkus WJ, Riley PA
    Thirty years of therapeutic innovation in melanoma research.
    Melanoma Res. 2021 Feb 18. pii: 00008390-900000000-99055.
    PubMed    


  268. OLOFSSON BAGGE R, Ny L, Ascierto PA, Hodi FS, et al
    The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials.
    Melanoma Res. 2021 Feb 18. pii: 00008390-900000000-99054.
    PubMed     Abstract available


  269. SARKAR M, Bhuniya A, Ghosh S, Sarkar A, et al
    Neem leaf glycoprotein salvages T cell functions from Myeloid-derived suppressor cells-suppression by altering IL-10/STAT3 axis in melanoma tumor microenvironment.
    Melanoma Res. 2021 Feb 18. pii: 00008390-900000000-99052.
    PubMed     Abstract available


  270. DOMINGUEZ-VARELA IA, Ancona-Lezama DA, Dalvin LA, Perez-Ramos EE, et al
    Choroidal melanoma treatment in times of coronavirus disease 2019.
    Melanoma Res. 2021 Feb 18. pii: 00008390-900000000-99051.
    PubMed    


  271. KERTYS M, Grendar M, Horak V, Zidekova N, et al
    Metabolomic characterisation of progression and spontaneous regression of melanoma in the melanoma-bearing Libechov minipig model.
    Melanoma Res. 2021 Feb 18. pii: 00008390-900000000-99050.
    PubMed     Abstract available


  272. ZHANG X, Su MW, Cheng Y, Martinka M, et al
    Immunohistochemistry analysis reveals lysyl oxidase-like 3 as a novel prognostic marker for primary melanoma.
    Melanoma Res. 2021 Feb 18. pii: 00008390-900000000-99049.
    PubMed     Abstract available


  273. RANTALA ES, Kivela TT, Hernberg MM
    Impact of staging on survival outcomes: a nationwide real-world cohort study of metastatic uveal melanoma.
    Melanoma Res. 2021 Feb 15. pii: 00008390-900000000-99057.
    PubMed     Abstract available


  274. MILLAN-ESTEBAN D, Garcia-Casado Z, Manrique-Silva E, Kumar R, et al
    KIT mutational status does not constitute an independent prognostic marker in cutaneous melanoma. A study on 688 Spanish patients.
    Melanoma Res. 2021;31:101-103.
    PubMed    


  275. ISMAIL RK, Sikkes NO, Wouters MWJM, Hilarius DL, et al
    Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases.
    Melanoma Res. 2021;31:58-66.
    PubMed     Abstract available


    January 2021
  276. ZHANG T, Li Q, Wang Q, Wang H, et al
    Diagnostic and prognostic value of heat shock protein 90alpha in malignant melanoma.
    Melanoma Res. 2021 Jan 22. pii: 00008390-900000000-99059.
    PubMed     Abstract available


  277. BENINATO T, Fuca G, Di Guardo L, Vetrano I, et al
    Immune-related Bell's palsy in melanoma patients treated with immune checkpoint inhibitors.
    Melanoma Res. 2021 Jan 22. pii: 00008390-900000000-99058.
    PubMed     Abstract available


    December 2020
  278. LUO X, Xu Y, Li Y, Zhang G, et al
    BAP1 deletion abrogates growth and metastasis of murine cutaneous melanoma.
    Melanoma Res. 2020;Publish Ahead of Print.
    PubMed     Abstract available


  279. ZAFAR FS, Richey P, Okereke U, Milhem M, et al
    Morphea following treatment with pembrolizumab for melanoma with metastatic lymph nodes: case report and review of literature.
    Melanoma Res. 2020;Publish Ahead of Print.
    PubMed     Abstract available


  280. HOLMAN BN, Van Gulick RJ, Amato CM, MacBeth ML, et al
    Clinical and molecular features of subungual melanomas are site-specific and distinct from acral melanomas.
    Melanoma Res. 2020;30:562-573.
    PubMed     Abstract available


  281. MIKKELSEN LH, Maag E, Andersen MK, Kruhoffer M, et al
    The molecular profile of mucosal melanoma.
    Melanoma Res. 2020;30:533-542.
    PubMed     Abstract available



  282. Paradox in melanoma: more patients fewer publications: Retraction.
    Melanoma Res. 2020;30:632.
    PubMed    


  283. IPENBURG NA, van der Hage JA, Newton-Bishop JA, Harland M, et al
    Sentinel node biopsy in cutaneous melanoma patients with germline CDKN2A mutations.
    Melanoma Res. 2020;30:630-631.
    PubMed    


  284. VELTER C, Sakkal M, Robert C
    Bariatric surgery in a patient treated with targeted therapies for metastatic melanoma: a case report.
    Melanoma Res. 2020;30:629-630.
    PubMed    


  285. AYAZ T, Ramachandran V, Loya A, Patel S, et al
    Impact of marital status on survival in cutaneous melanoma.
    Melanoma Res. 2020;30:628-629.
    PubMed    


  286. MARCAILLOU M, Linder C, Chaltiel L, Sibaud V, et al
    PD-1 inhibitors might limit the development of brain metastases in patients with advanced melanoma.
    Melanoma Res. 2020;30:580-589.
    PubMed     Abstract available


    November 2020
  287. MURRIA ESTAL R, de Unamuno Bustos B, Perez Simo G, Simarro Farinos J, et al
    MicroRNAs expression associated with aggressive clinicopathological features and poor prognosis in primary cutaneous melanomas.
    Melanoma Res. 2020 Nov 23. doi: 10.1097/CMR.0000000000000709.
    PubMed     Abstract available


  288. NUNEZ ABAD M, Saval Victoria A, Franco La Rosa M, Berrocal A, et al
    Infusion reaction to nivolumab in a metastatic melanoma patient. Safe switch to another anti-programmed death-1: a case report.
    Melanoma Res. 2020 Nov 23. doi: 10.1097/CMR.0000000000000710.
    PubMed     Abstract available


  289. HODI FS, Chapman PB, Sznol M, Lao CD, et al
    Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218).
    Melanoma Res. 2020 Nov 23. doi: 10.1097/CMR.0000000000000708.
    PubMed     Abstract available


  290. DUDDA M, Mann C, Heinz J, Schmidgen I, et al
    Hemophagocytic lymphohistiocytosis of a melanoma patient under BRAF/MEK-inhibitor therapy following anti-PD1 inhibitor treatment: a case report and review to the literature.
    Melanoma Res. 2020 Nov 23. doi: 10.1097/CMR.0000000000000703.
    PubMed     Abstract available


  291. LIU WK, Naban N, Kaul A, Patel N, et al
    Life-threatening polymyositis with spontaneous hematoma induced by nivolumab in a patient with previously resected melanoma.
    Melanoma Res. 2020 Nov 13. doi: 10.1097/CMR.0000000000000706.
    PubMed     Abstract available


  292. BAO R, Surriga O, Olson DJ, Allred JB, et al
    Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target.
    Melanoma Res. 2020 Nov 6. doi: 10.1097/CMR.0000000000000701.
    PubMed     Abstract available


  293. ANDERSON TS, Wooster AL, La-Beck NM, Saha D, et al
    Antibody-drug conjugates: an evolving approach for melanoma treatment.
    Melanoma Res. 2020 Nov 6. doi: 10.1097/CMR.0000000000000702.
    PubMed     Abstract available


  294. CYBULSKA-STOPA B, Zietek M, Kaminska-Winciorek G, Czarnecka AM, et al
    Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients.
    Melanoma Res. 2020 Nov 6. doi: 10.1097/CMR.0000000000000705.
    PubMed     Abstract available


  295. BENIEY M, Tran A, Boulva K
    Mapping sentinel lymph nodes in cutaneous melanoma: a vast array of perioperative imaging modalities.
    Melanoma Res. 2020 Nov 5. doi: 10.1097/CMR.0000000000000704.
    PubMed     Abstract available


    October 2020
  296. FARRICHA V, Quaglino P, Brizio M, de Terlizzi F, et al
    Safety and efficacy of electrochemotherapy in a series of patients with nonmetastasized primary or recurrent anorectal malignant melanoma.
    Melanoma Res. 2020 Oct 8. doi: 10.1097/CMR.0000000000000699.
    PubMed     Abstract available


    September 2020
  297. LEE S, Suh HB, Choi SJ, Kang J, et al
    Identification of prognostic mRNAs in metastatic cutaneous melanoma.
    Melanoma Res. 2020 Sep 29. doi: 10.1097/CMR.0000000000000697.
    PubMed     Abstract available


  298. MATTEI J, Ballhausen A, Bassett R, Shephard M, et al
    A phase II study of the insulin-like growth factor type I receptor inhibitor IMC-A12 in patients with metastatic uveal melanoma.
    Melanoma Res. 2020 Sep 21. doi: 10.1097/CMR.0000000000000694.
    PubMed     Abstract available


  299. CHANG LW, Badal B, Lu CJ, Solovyov A, et al
    An integrative approach identifies dysregulated long non-coding RNAs as microRNA decoys during nevus to melanoma transformation.
    Melanoma Res. 2020 Sep 21. doi: 10.1097/CMR.0000000000000695.
    PubMed     Abstract available


  300. BYRON Y, Nott L, Shackleton M
    Case report: acute tumour lysis syndrome following encorafenib and binimetinib for v600E metastatic melanoma with large intra-abdominal mass.
    Melanoma Res. 2020 Sep 21. doi: 10.1097/CMR.0000000000000696.
    PubMed    


    April 2020
  301. ROS-MONTANA J, Saoudi-Gonzalez N, Ortiz-Velez C, Munoz-Couselo E, et al
    The role of ipilimumab after anti-PD-1 treatment: two case reports and a literature review.
    Melanoma Res. 2020;30:209-212.
    PubMed     Abstract available


  302. TRUONG A, Hyngstrom JR, Andtbacka RHI, Noyes RD, et al
    Recurrence risk of early-stage melanoma of the external ear: an investigation of surgical approach and sentinel lymph node status.
    Melanoma Res. 2020;30:173-178.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.